{"certainAgreement":{"otherDetails":"PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"A planned interim efficacy analysis was performed after 42 events (death or progression). The final analysis was planned to occur after 67 events. The Data Monitoring Committee (DMC) recommended releasing the interim results for early reporting and these results are considered the final study results."},"pointOfContact":{"email":"seiferheldw@nrgoncology.org","organization":"NRG Oncology","phone":"215-574-3208","title":"Wendy Seiferheld"}}